Get latest articles and stories on India at LatestLY. The Serum Institute of India (SII) has sought permission from the country s drug regulator to conduct Phase-3 trial to evaluate the safety and immunogenicity of its COVID-19 vaccine Covovax as a booster dose in children aged two to 18 years, official sources said on Sunday. India News | SII Seeks Permission for Phase-3 Trial of Covovax as Booster Dose in Children Aged 2 to 18 Years.
The Drugs Controller General of India (DCGI) had granted permission in March for conducting Phase-3 clinical trial of Covovax as a booster dose in adults.
Serum Institute of India (SII) Director for Government and Regulatory Affairs Prakash Kumar Singh had written to the Union Health Ministry recently, requesting for Covovax s inclusion in the immunisation drive for children aged 12 to 17 years, , Covavax, serum institute of india
Get latest articles and stories on India at LatestLY. Children aged 12 to 17 years can now get the Serum Institute s coronavirus vaccine Covovax at private centres with a provision for it being made on the CoWIN portal, official sources said on Monday. India News | SII s Covid Vaccine Covovax Now Available for 12-17 Age Group at Private Centres.